Clinical Trials Logo
NCT number NCT01710098
Study type Observational
Source United Clinic Management GmbH
Contact Leopold Durner, MD
Phone +49-89-85693-0
Status Recruiting
Phase N/A
Start date June 2012
Completion date June 2014

Clinical Trial Summary

How are testosterone levels of patients with prostate cancer under treatment with Firmagon® changing.

Former studies showed a quick fall of testosterone levels after start of therapy with Firmagon® and a quick recovery when therapy is stopped. The investigators want to prove this in a normal outpatient urologist setting. Furthermore data is collected to prove the adherence to the German S3-Guideline for the treatment of prostate cancer.

Clinical Trial Description


Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

See also
Status Clinical Trial Phase
 Recruiting NCT02911922 - Randomized Trial of Image -Guided Stereotactic Radiation Therapy (IG-SRT) in Prostate Cancer N/A
 Recruiting NCT02906241 - PACCT: Partnering Around Cancer Clinical Trials N/A
 Recruiting NCT02886598 - Safety and Efficacy of Firmagon® (Degarelix) for Injection N/A
 Recruiting NCT02916537 - A Phase 1 Trial for Safety and Imaging Evaluation of CTT1057, a Small Molecule Inhibitor of Prostate Specific Membrane Antigen (PSMA) Phase 1
 Recruiting NCT02918357 - Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence Phase 2/Phase 3
 Recruiting NCT02917161 - Prostatic Artery Embolization Before Radical Prostatectomy in Prostate Cancer: A Proof-of-concept Study N/A
 Recruiting NCT02919111 - Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients Phase 2/Phase 3
 Recruiting NCT02723734 - Validation Study on the Impact of Decipher® Testing - VANDAAM Study N/A
 Recruiting NCT02766543 - Pivotal Study of MRI-guided Transurethral US Ablation to Treat Localized Prostate Cancer Phase 2
 Recruiting NCT02766686 - Preference-based Comparative Study on Definitive Radiotherapy of Prostate Cancer With Protons Phase 2
 Recruiting NCT02747342 - A Trial of SHR3680 in Metastatic Castration-Resistant Prostate Cancer as Monotherapy Phase 1
 Not yet recruiting NCT02887976 - Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201 Phase 3
 Not yet recruiting NCT02816840 - PET-CT/MRI in the Radiotherapy for Prostate Cancer Phase 1/Phase 2
 Not yet recruiting NCT02840552 - The Safety and Efficacy of 18F-Fluoromethylcholine (18F-FCH) PET/CT in Prostate Cancer Phase 3
 Not yet recruiting NCT02886546 - Utility of Dynamic Variables Measured by Calibrated Pulse Contour Analysis of Oesophageal Doppler Monitor for Predicting Fluid Responsiveness During Robot-Assisted Laparoscopic Prostatectomy N/A
 Not yet recruiting NCT02903368 - Neoadjuvant And Adjuvant Abiraterone Acetate + Aptilutamide Prostate Cancer Undergoing Prostatectomy Phase 2
 Not yet recruiting NCT02911649 - Reducing Sedentary Behaviour With Technology N/A
 Not yet recruiting NCT02905318 - Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer Phase 2
 Recruiting NCT02600156 - Focal Laser Ablation of Prostate Cancer Tumors N/A
 Recruiting NCT02559115 - 68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer Phase 2